Fibromyalgia, Menopause, Sleep-Wake disorders
Conditions
Interventions
60 women will use transdermal estradiol gel, 0,06%, two pumps daily, for 90 days. Women who have an intact uterus must take micronized progesterone soft capsule, 100mg, oral, daily, for 90 days
Drug
Sponsors
Hospital de Clínicas da Universidade Federal do Paraná
Sociedade Evangélica Beneficente de Curitiba
Eligibility
Sex/Gender
Female
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Menopausal women with fibromyalgia; with 40 to 60 years old,; and presenting climacteric symptoms
Exclusion criteria
Exclusion criteria: There will exclude from the study the women who won't be able to comprehend and reply the questionnaires due to their limited cognition or idiomatic; the ones who have presented another associated autoimmune rheumatic disease (systemic lupus erythematosus, rheumatoid arthritis); the patients who have absolute contraindication to the hormone replacement therapy ( breast cancer, endometrium cancer, acute an prior thromboembolism, acute or/ and severe liver disease, acute heart disease and uterine bleeding no diagnosed)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects of the hormone therapy on the impact of Fibromyalgia, evaluated by FIQ-R (Fibromyalgia Impact Questionnaire-Revised), questionnaire validated for use in Brazil. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of the hormone therapy on quality of life and sleep evaluated by scores of UQOL ( Utian Quality of life questionnaire); PSQI (Pittsburg Sleep Quality Index), all validated for use in Brazil. | — |
Countries
Brazil
Contacts
Public ContactRejane Dias
Hospital de Clínicas da Universidade Federal do Paraná
Outcome results
None listed